Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2024-09-11 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company regarding the shareholding details of the top ten shareholders and top ten unrestricted shareholders as of a specific date (September 10, 2024). It references a board meeting approving a share repurchase plan and provides detailed shareholding data. The content focuses on share ownership and repurchase plans rather than financial results, management changes, or regulatory filings. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document length is short and it is not a report publication announcement or a certification. Therefore, the appropriate classification is POS.
2024-09-11 Chinese
福建天衡联合律师事务所关于大博医疗科技股份有限公司2024年股票期权激励计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a company's 2024 stock option incentive plan. It extensively discusses the legal compliance, conditions, procedures, and specifics of the stock option plan, including references to relevant laws, regulations, and company governance. The document is not a financial report, earnings release, or regulatory announcement but a legal opinion related to a capital incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it pertains to company fundraising and capital structure changes through stock option incentives.
2024-09-10 Chinese
2024年股票期权激励计划首次授予激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of initial stock option incentive plan recipients for the year 2024 by 大博医疗科技股份有限公司 (DaBo Medical Technology Co., Ltd.). It contains detailed names, positions, and stock option quantities allocated to core management and technical personnel. The document is dated September 11, 2024, and is issued by the company's board of directors. There is no financial statement, earnings data, or regulatory certification present. The content focuses on the allocation of stock options to management and key personnel, which is a form of remuneration or incentive disclosure. This type of document aligns with Remuneration Information filings, which detail compensation and incentive plans for executives and directors. It is not an announcement of a report, nor a full financial report, nor a regulatory filing or proxy solicitation. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2024-09-10 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from a company about its plan to repurchase its own shares using its own funds through a stock exchange. It includes specifics about the number of shares to be repurchased, price limits, purpose (for equity incentive plans), funding sources, risk disclosures, authorization by the board, and compliance with regulatory requirements. The document is titled '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It is not a financial report like an annual or quarterly report, nor is it a regulatory filing or announcement of a report publication. It is a formal disclosure about the company's share repurchase plan, which fits the category of 'Transaction in Own Shares' (POS). The document length is sufficient and contains substantive details about the repurchase plan, not just a brief announcement or certification. Therefore, the correct classification is POS with high confidence.
2024-09-10 Chinese
大博医疗科技股份有限公司2024年股票期权激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "大博医疗科技股份有限公司 2024 年股票期权激励计划（草案）" which translates to "Dabo Medical Technology Co., Ltd. 2024 Stock Option Incentive Plan (Draft)". It is a detailed draft plan for a stock option incentive program, including the purpose, management, scope, conditions, and terms of the stock option plan. The document includes legal references, detailed terms of the stock option grant, eligibility, performance targets, and governance related to the incentive plan. It is not a financial report, earnings release, or regulatory filing per se, but a detailed plan related to executive and employee remuneration through stock options. This type of document fits best under Remuneration Information (DEF 14A) as it details compensation plans for executives and key personnel through stock options. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the classification is DEF 14A with high confidence.
2024-09-10 Chinese
关于召开2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about the convening of the 2024 second extraordinary general meeting of shareholders for the company 大博医疗科技股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and notification about the shareholder meeting and voting process. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-09-10 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.